Serina Therapeutics
23 hedge funds and large institutions have $2.54M invested in Serina Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
34% more capital invested
Capital invested by funds: $1.9M → $2.54M (+$641K)
0.76% more ownership
Funds ownership: 3.38% → 4.14% (+0.76%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 25 → 23 (-2)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$485K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$75.2K |
| 3 |
BlackRock
New York
|
+$49.5K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$216 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$17 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$74.8K |
| 2 |
Millennium Management
New York
|
-$60.8K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$20K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.17K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.24K |
SER Hedge Fund Activity: Q2 2025 in Review
23 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q2 2025, worth a combined $2.54M — up 34% from $1.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SER and 3 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $485K. The largest seller was Citadel Advisors, exiting entirely with an estimated $74.8K sold.
- 23 institutional investors held Serina Therapeutics (SER) as of Q2 2025, down from 25 in Q1 2025.
- Funds reported $2.54M of Serina Therapeutics stock for Q2 2025, up 34% quarter-over-quarter.
- 3 funds opened new Serina Therapeutics positions in Q2 2025 and 5 closed out, a net change of -2 holders.
- The largest Serina Therapeutics buyer in Q2 2025 was Vanguard Group, an estimated $485K added.
- The largest Serina Therapeutics seller in Q2 2025 was Citadel Advisors, an estimated $74.8K sold.
Based on aggregated 13F filings for Q2 2025.